Back Into IMCL

Investing note:  I reopened my long position in ImClone Systems (NASDAQ: IMCL) today @ 40.50.  The negative effect from the news release earlier this week wasn't nearly as strong as I thought it was going to be.  My expectation is that there is going to be a healthy run in this stock at some point between now and mid June, and after struggling with this one for so long I just don't want to miss it.  Naturally there is risk, but we already know IMCL will be moving into 2nd and 1st line colorectal cancer treatment, so the downside risk is somewhat mitigated.